- In June 2023, Merck KGaA launched a new line of CRISPR-edited human cell lines designed for accelerated drug discovery, enabling researchers to identify novel therapeutic targets with greater efficiency and precision.
- In March 2024, Thermo Fisher Scientific introduced the Gibco™ CTS™ Cell Lines, incorporating advanced gene editing capabilities to support scalable cell-based therapies for regenerative medicine and vaccine production.
- In January 2024, Lonza Group AG announced a strategic partnership with a leading biopharmaceutical company to develop customized immortalized cell lines for monoclonal antibody production, enhancing scalability and efficiency in bioprocessing.
- In September 2023, ATCC expanded its portfolio of human cell lines with new cancer-specific lines, designed to support high-throughput screening and precision oncology research.
- In April 2023, FUJIFILM Irvine Scientific launched a new serum-free cell culture media optimized for immortalized cell lines, improving cell growth and reproducibility in large-scale bioprocessing applications.
